AIM: These studies were performed to test the hypothesis that endogenous neuropeptide Y (NPY) acting on the NPY Y 5 receptor subtype contributes to the control of food intake. The hypothesis was tested using S 25585Fa newly synthesized NPY Y 5 receptor antagonist. METHODS AND RESULTS: S 25585 was shown to be a high-affinity antagonist of the NPY Y 5 receptor subtype (IC 50 5 nM) with no significant affinity toward other NPY receptor subtypes and over 40 other receptors, channels or uptake systems. S 25585 (7.5 mg/kg, i.p.) did not induce a conditioned taste aversion, significantly alter need-induced sodium appetite or induce pica, suggesting that at this dose the compound did not induce illness or malaise. In satiated rats, S 25585 (5.0 and 7.5 mg/kg, i.p.) significantly decreased the overfeeding induced by i.c.v. injection of NPY (1 mg) and the highly selective NPY Y 5 receptor agonist [hPP 1À17 , Ala 31 , Aib 32 ]NPY (0.7 mg). In rats fasted for 4 h immediately before the dark phase, analysis of the microstructure of feeding behavior revealed that S 25585 significantly increased latency to eat and significantly decreased the duration and size of the meals without altering the meal number or eating rate. Analysis of the behavioral satiety sequence at this time revealed that the animals passed through the normal pattern of feeding, grooming and resting. Although S 25585 appeared to be influencing a physiological system controlling appetite, this does not involve the NPY Y 5 receptor since the antagonist also markedly reduced food intake in the NPY Y 5 knockout mouse.
Introduction
Many studies have shown neuropeptide Y (NPY) to exert a powerful stimulatory effect on food intake after injection or infusion into the cerebral ventricles or into the hypothalamus of satiated rats. [1] [2] [3] Evidence for an important physiological role of NPY in the control of food intake and body weight has come from several lines of studies. First, NPY levels in the hypothalamus and food intake are closely related. For example, hypothalamic NPY levels are increased in the runup to the dark phase when rats begin to consume the majority of their daily food intake. 4 Second, hypothalamic NPY levels are increased in animal models of hyperphagia such as after food deprivation or experimentally induced diabetes. 5 Finally, inhibition of NPY synthesis or blockade of the actions of NPY with antibodies, NPY-antisense oligonucleotides or receptor antagonists has been shown to decrease food intake in both free-feeding and energy-deprived animals. [6] [7] [8] Taken together, these observations strongly suggest that NPY plays a physiologically important role in the control of food intake and, as such, represents a potential therapeutic target for the development of appetite-suppressing drugs. The recent finding that the acions of NPY are mediated through at least five different receptor subtypes raises the possibility that the effects of NPY on appetite may be mediated through a specific receptor subtype. 9 In this case, blockade of the receptor linked to food intake would ameliorate the possibility of influencing the expression of other NPY-induced behaviors, which could lead to expression of potentially undesirable side effects. 10 Although evidence exists for the involvement of the NPY Y 1 receptor in the control of food intake, association studies have shown that the ability of a range of NPY peptides to stimulate food intake correlates best with their affinity for the NPY Y 5 receptor. 11 Furthermore, several newly synthesized peptides with high selectivity for the NPY Y 5 receptor have been shown to stimulate appetite dramatically. [12] [13] [14] [15] However, it is unclear whether the NPY Y 5 receptor plays a dominant role in mediating the actions of endogenous NPY on food intake. This is because after release in the hypothalamus, NPY would be expected to stimulate not just the NPY Y 5 receptor but all receptors involved in the control of appetite such as the NPY Y 1 and NPY Y 2 subtypes. 16, 17 Blockade of the NPY Y 5 receptor may not then be effective since food intake could be maintained by an action of NPY on the Y 1 and Y 2 subtypes and other neural systems. Currently, only conflicting evidence exists regarding the role of the NPY Y 5 receptor in mediating the effects of endogenous NPY on food intake. For example, administration of antisense oligodeoxynucleotides directed against the NPY Y 5 receptor has been shown to suppress appetiteFbut not in all studies. 18, 19 Furthermore, knockout of the NPY Y 5 receptor presents an eventually obese phenotype, 20 while selective NPY Y 5 receptor antagonists have been shown either to influence or have no effect on food intake. 21, 22 Therefore, the purpose of these studies was to reassess the hypothesis that the NPY Y 5 receptor plays a physiologically important role in the control of food intake. The newly synthesized NPY Y 5 antagonist S 25585 was used to test this hypothesis.
Methods

Animals
These experiments were conducted with male Wistar and male Long-Evans rats of 6 weeks of age weighing 325-350 g, together with male NPY Y 5 knockout mice and male 129/SV Pasico mice (Iffa Credo, L'arbresle, France). The animals were housed individually in a room with a 12 h/12 h light/dark cycle (lights on 0730) at 22731C and 55% relative humidity. Normal food and tap water were available to the animals at all times unless otherwise stated. All animal procedures described in this study complied with French laws regulating animal experimentation (Decree No. 87-848 (19 October 1987) 4 and NPY Y 5 receptors, respectively. The incubations were terminated by rapid filtration through Schleider and Schuell #32 glass filters that had previously been soaked in 1% polyethyleneimine using a cell harvester filtering apparatus (Brandel Instruments, Gaithersburg, MD, USA). For both the human and rat receptors, nonspecific binding was measured in the presence of 1 mM unlabelled PYY or pNPY, respectively. Ligand displacement of more than 30% at 100 nM prompted the construction of full displacement curves and the calculation of K i values.
Implantation of intraventricular cannulae
Wistar rats were anesthetized with sodium pentobarbital (60 mg/kg i.p.; Sanofi, Libourne, France) and stainless-steel guide cannulae (Plastic Products Co, Roanoke, VA, USA) were stereotaxically implanted into the right lateral ventricle at the following coordinates relative to the bregma: AP À0.8 mm, L ¼ À1.2 mm and V ¼ À3.5 mm. After a 7-day recovery period, during which the animals were handled every day to minimize nonspecific stress, they were lightly anesthetized with Forène (Abbott Laboratories, Queenborough, UK). Human/rat NPY (1 mg in a volume of 2.5 ml, Neosystem S.A. Strasbourg, France) was then injected through the intraventricular cannulae. Immediately after injection, the animals quickly recovered and were returned to their home cages. Only those animals responding within 2 h with a robust increase in food intake, indicating correct cannulae placement, were used in the following experiments. After 2 days, the rats were randomly assigned to different groups and studied in one of the following protocols.
NPY-and [hPP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , Ala 31 , Aib 32 ]hNPY-induced food intake In these studies, the animals were habituated for at least 2 weeks before experiment to a diet of 6 mm diameter food pellets of the following composition: 67.5% food flour, 26.5% saccharose, 5% gum tragacanth, 1.25% magnesium stearate (A03 UAR, Orge, France). The food pellets were present in a metal food hopper attached to the inside of the cages. On the day of the study, rats were injected intraperitoneally either with S 25585 (2.5, 5.0 or 7.5 mg/kg) or an equal volume of the 10% solutol/10% DMSO vehicle (3 ml/ kg). At 1 h after drug or vehicle treatment, each animal received either an injection of h/r NPY (1 mg), [hPP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] ]hNPY (0.7 mg) or an equivalent volume of the artificial cerebrospinal fluid into the right lateral ventricle (2.5 ml). Measurements of food intake were made at different times after peptide injection. Food spillage was carefully quantified during each time period and corrected for this loss. At the end of the experiments, the animals were euthanized and the position of the cannulae was assessed by the injection of 100 ml of Evans blue dye (2 mg/ml) followed by visual examination of brain slices. Only data obtained from animals with correctly positioned cannulae were included in the final data analysis.
Conditioned taste aversion
These experiments were performed according to previously described methods. 25 In brief, Wistar rats were individually housed in plastic cages with free access to normal food and water. During a 7-day habituation period, the water bottle was removed from the cages overnight (1600-1000). At 1000, water was then made available to the animals from 250 ml plastic bottles to which a normal drinking spout was attached. The bottles were weighed before and after presentation to the animals to determine the quantity of water ingested during this period. After 4 days of this treatment regime, which served to habituate the animals to the experimental protocol and to randomize the animals, 0.2% saccharine was presented instead of water (Test 1). At 20 min after the test period, the animals were injected i.p. either with lithium chloride (75 mg/kg), S 25585 (2.5, 5.0 and 7.5 mg/kg) or the 10% solutol/10% DMSO vehicle (3 ml/ kg). After 4 days, the consumption of saccharine was again determined (Test 2). Considerable care was taken in these experiments to first prevent and then to quantify any leakage of saccharine solution during the presentations.
Sodium appetite
These experiments were performed according to previously described methods. 26 In brief, Long-Evans rats were individually housed in plastic cages with free access to normal food. After a 7-day habituation period, rats were injected twice with furosemide (5 mg/kg, i.p.) or twice with an equivalent volume of the isotonic saline vehicle (2 ml/kg, i.p.). A period of 1 h separated the two injections. Those animals injected with furosemide then received only the sodium-deficient diet (ICN Pharmaceuticals, Costa Mesa, CA, USA) to facilitate the process of sodium depletion. At 24 h after injection, food was removed from the cages and both the furosemide-and saline-treated animals were administered either isotonic saline (3 ml/kg), LiCl (76 mg/ kg, i.p.), S 25585 (2.5, 5.0 or 7.5 mg/kg, i.p.) or an equivalent volume of the 10% solutol/10% DMSO vehicle (3 ml/kg, i.p.). Just after the injection, all animals were presented with a solution of 0.5 M saline and the quantity consumed recorded over a 2 h period. Owing to the large quantity of animals used, these experiments were conducted over a period of 3 weeks with three groups of three to four furosemide-treated animals and three to four saline-treated control animals.
Pica
These experiments were performed with modifications to previously described methods. 26 Rats were individually housed in wire-bottomed plastic cages with free access to both 6 mm diameter food pellets (A03 UAR) and kaolin powder. The food pellets were present in a small porcelain bowl on the floor of the cage. The kaolin powder was present in a metal feeding dish attached to the inside of the cage. After a 2-week habituation period to these conditions, the animals were randomized into five treatment groups based upon the quantity of food eaten during the stabilization period. In addition, those rats that consistently spilt the kaolin powder were eliminated from the study. At 1 day after randomization, the animals were injected just before the beginning of the dark phase either with cyclophosphamide (100 mg/kg, i.p.), S 25585 (2.5, 5.0 or 7.5 mg/kg, i.p.) or an equivalent volume of the 10% solutol/10% DMSO vehicle (3 ml/kg). After injection, the quantity of kaolin and food ingested over the following 24 h period was determined. Food or kaolin spilt by the animals was collected at the end of the experiment and total food and kaolin intake was corrected for this loss.
Behavioral satiety sequence
The behavioral satiety sequence (BSS) was determined using minor modifications of the continuous behavioral analysis method described previously in detail. 27 In these experiments, Wistar rats were maintained on sawdust in individual plastic cages of the following sizeFheight 18.5 cm, width 23 cm, length 35 cm. The rats were provided with normal food and water and remained in these 'home' cages within the same room under a 12 h light/dark cycle (0500-1700 light) for the duration of the experiment. Normal food was used to mimic as accurately as possible the other feeding experiments in this study and to avoid the pleasure component that is clearly present when animals are presented with wet mash food. 27 After a 5-day stabilization period, food was removed from the cages from 1300 to 1700 and the animals were injected with isotonic saline (3 ml/kg, i.p.) at 1600. This treatment regime continued every day for 3 days and served to habituate the animals to the final experimental protocol. At 1600 on the day of the study, each rat was injected either with S 25585 (7.5 mg/kg, i.p.) or an equivalent volume of the 10% solutol/10% DMSO vehicle (3 ml/kg, i.p.). After 45 min, two video cameras were placed in close proximity to the cage containing the animals. One video camera (Panasonic WV-BP130/GE; Suzhou Matsushita Communication Industrial Co., Ltd, Suzhou, China) was placed 10 cm in front of the cage and the other was placed 10 cm from the right side of the cage. The cameras provided a high-definition black and white image of the rats from two different angles, which facilitated an accurate assessment of their behavior. After 15 min, food pellets (UAR 03) were placed into the food hopper of the cage lid. The room lights were switched off and illumination was provided with a low wattage red lamp. The animals were then recorded on video tape in the absence of the investigator for a 35 min period (Panasonic TL 300 Timelapse VCR, Matsushita Electric Ind. Co., Ltd, Osaka, Japan). In these experiments, the animals were studied in groups of two in a random sequence. At a later date, the video tapes from both views of each animal were played back. For each 5 min of the 35 min experimental period, both the frequency and the amount of time the animals exhibited eating, drinking, grooming, activity, resting, sniffing and rearing were assessed. These behaviors were monitored by two independent observers who then averaged their numbers. Variation in the assessment between the two observers was less than 6%. The following definitions of the component behaviors of the BSS were used in the analysis of these studies: 27 eatingFbiting, gnawing or swallowing food from the food hopper or from front paws; drinkingFlicking water bottle nozzle; groomingFscratching, licking or biting the coat, whiskers, feet or genitals; activityFmovements involving all four limbs, such as walking around the cage; restingFsitting or lying in a resting position; sniffingFrapid wrinkling of nose directed at some aspect of the environment, head movement; rearingFfront paws raised from the cage floor and either placed on the side of the cage or placed in front of the body.
Microstructure of ingestive behavior
The TSE Drinking and Feeding Monitor was used to analyze the microstructure of ingestive behavior in these experiments (TSE Technical & Scientific Equipment GmbH, D-61350 Bad Homburg, Germany). Wistar rats were placed individually into plastic cages to which were attached both a feeding and drinking sensor. The basket of the feeding sensor was filled with normal food pellets and the drinking bottle was filled with tap water. In this system, food intake is measured continuously as a decrease in the weight of the food basket and water intake as decrease in the pressure exerted on a sensor at the bottom of the water bottle. The motility of the rats was also determined in these experiments using the MoTil s system (TSE) that was placed around the base of each cage. This system consists of infrared light beams placed across the bottom of the cage, the output of which is disrupted by the movement of the animal. These studies followed exactly the same protocol as described above for the BSS except that the microstructure of food and water intake as well as animal motility was measured.
Food intake in NPY Y 5 receptor knockout mice In these experiments, both NPY Y 5 knockout and control mice were individually housed in sawdust-littered plastic cages in a room with a 0500-1700 light cycle and fed the 6 mm food pellets described above. The pellets were contained in a metal food hopper attached to the inside of the cages and above a grid that facilitated the collection of spilled food. After a habituation period of 2 weeks, food intake and body weight were measured over consecutive 24 h periods (1700-1700). After 7 days of measurement, the animals were randomized into two groups, based on their food intake over the preceding 24 h period and on their body weight. The mice were then injected twice daily (0900 and 1600) either with S 25585 (7.5 mg/kg, i.p.) or the solutol/10% DMSO vehicle (2.5 ml/kg, i.p.) for 4 days. The quantity of drug administered to the animals was deliberately kept as low as possible to minimize nonselective interactions and to match that given to the rats in the other protocols of these studies. The quantity of food eaten over each 24 h period (1700-1700) was then determined and corrected for spillage. Body weight was measured at 0900 immediately before the first drug injection.
Data and statistical analysis
Data are grouped together and presented as mean7s.e.m. The individual statistical tests that were used in these studies are described in detail in the figure legends. In each case Pvalues of o0.05 were considered to be statistically significant.
Materials
The NPY Y 5 knockout mice used in these studies were originally obtained as a breeding pair from Dr Richard D Palmiter at the University of Washington and transferred to Iffa Credo for the establishment of a Servier breeding colony. 28 Both the NPY Y 5 knockout and the 129/SV Pasico mice that were used as controls were subjected to genetic analysis that revealed a 93-100% similarity between the two strains. RT-PCR revealed the presence of mRNA encoding for the NPY Y 5 receptor in the control strain and its complete absence in the knockout mice. 
Results
Binding of S 25585 to human and rat NPY receptors ( 
Conditioned taste aversion (Figure 2)
The results show that consumption of saccharine during the first exposure was well matched between the five experimental groups (top panel). The subsequent injection of the solvent or S 25585 (2.5, 5.0, 7.5 mg/kg) did not significantly Figure 1 Chemical structure of S 25585. Figure 2 Conditioned taste aversion. After a habituation period to the experimental protocol, the animals were presented with 0.2% saccharine for 20 min after removing the drinking water for 18 h (Test 1). The animals were then injected i.p. with either isotonic saline (control absolute), lithium chloride, S 25585 or an equivalent volume of the 10% solutol/10% DMSO vehicle (3 ml/kg). After 4 days, the animals were presented with 0.2% saccharine, and the quantity consumed during a 20 min period was determined (Test 2). Results are expressed as the mean7s.e. from eight animals in each group. Statistics by one-way analysis of variance was followed by the Student-Neuman-Keuls test that compared all groups with the solvent controls. *Po0.05 vs controls. CTRL ¼ control.
affect saccharine consumption when this substance was represented to the animals 4 days later (bottom panel). In contrast, injection of lithium chloride resulted in a large significant decrease in saccharine consumption from solvent control levels.
Salt appetite (Figure 3)
The results in Figure 3 (top panel) show that in sodium-replete animals, neither the injection of the solvent, lithium chloride (76 mg/kg) nor S 25585 (2.0, 5.0 and 7.5 mg/kg) significantly affected consumption of the 0.5 M sodium chloride solution. Compared to animals administered isotonic saline, injection of the solvent also had no significant effect on the consumption of saline in sodium-depleted rats ( Figure 4 , bottom panel). However, compared to the solventtreated control animals, injection of lithium chloride (76 mg/kg) produced a statistically significant fall in 0.5 M saline consumption.
Pica (Figure 4)
The results show that control rats ingested approximately 2971 g of food, but ate very little kaolin (0.0670.02 g) during the 24 h study period. In contrast, when the animals were rendered ill with cyclophophamide (100 mg/kg), they significantly decreased their consumption of food and significantly increased their consumption of kaolin. Although the consumption of kaolin was unchanged in the 24 h period after the injection of S 25585, the highest dose administered (7.5 mg/kg) induced a small but statistically significant decrease in food intake from vehicle-injected controls (À6.4 g). depleted at the time of the study. The animals were injected i.p. with either isotonic saline (control absolute), lithium chloride, S 25585 or an equivalent volume of the 10% solutol/10% DMSO vehicle (3 ml/kg), and the quantity of 0.5 M saline consumed during a 2 h test period was determined. Results are expressed as the mean7s.e. from eight observations in each group of sodiumreplete animals and 11 observations in each group of sodium-depleted animals. Statistics by one-way analysis of variance was followed by the Student-Neuman-Keuls test that compared all groups with the solvent controls. *Po0.05 vs controls. CTRL ¼ control. subtype, it is not absolutely specific. Therefore, the activity of this peptide was studied at a dose of 0.7 mg in order to minimize the possibility of interactions with other NPY receptor subtypes. Even at a dose of 0.7 mg, ventricular Figure 5 NPY-and [hPP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , Ala 31 , Aib 32 ]hNPY-induced food intake. Differing doses of S 25585 or an equivalent volume of the 10% solutol/10% DMSO vehicle (3 ml/kg) were injected intraperitoneally. After 1 h, rats received an injection of either h/r NPY (1 mg), [hPP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , Ala 31 , Aib 32 ]hNPY (0.7 mg) or an equivalent volume of the artificial CSF vehicle (2.5 ml). Cumulative food intake over the following 5 h period after S product administration is shown in this figure connected by spline curves. Results are expressed as mean7s.e. Statistics by two-way analysis of variance (unweighted means analysis) was followed by the Student-Neuman-Keuls test that compared all groups of animals.
þ P40.05 control vs NPY or control vs [hPP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , Ala Behavioral satiety sequence ( Figure 6 ) In these studies, rats were fasted for 4 h immediately before the dark phase and then the food was represented. The durations of the behaviors that comprise the BSS were then observed during 5 min intervals over the following 35 min period. In these studies, the administration of S 25585 induced only a significant decrease in feeding duration and a significant increase in resting duration. All the other measured behaviors did not change significantly in response to drug treatment (results not shown).
The results demonstrate the BSS observed in both control and S 25585-treated animals. In control animals, each individual bout of eating was followed by a bout of grooming that progressed to a final phase of predominantly resting behavior. This behavioral progression represents the normal expression of the BSS. The administration of S 25585 did not greatly affect the general pattern in which the individual behaviors of the BSS were expressed, since the periods of eating behavior were followed by periods of grooming and by a final period of mainly resting behavior.
Microstructure of food intake during the time period of the BSS (Table 2) Compared to saline-injected controls, injection of the solvent had no significant effect on any measured parameter of food intake in 4 h fasted animals. Treatment with S 25585 significantly decreased total food intake and significantly increased eating latency. S 25585 reduced food intake in these experiments by decreasing the meal size and meal duration without significantly changing either the number of meals eaten, the eating rate or the overall motility of the animals.
Effect of S 25585 on food intake in NPY Y 5 knockout mice (Figure 7)
The results show that S 25585 (2 Â 7.5 mg/kg/day) produced a small and inconsistent decrease in food intake with no significant change in body weight in 129/SV Pasico mice. In contrast, when administered at the same dose to NPY Y 5 knockout mice, S 25585 produced a significant decrease in food intake during the first 2 days of administration. Food intake thereafter returned to control levels, despite continuing drug administration. The fall in food intake was associated with a marked and significant reduction in body weight in the NPY Y 5 knockout mice.
Discussion
Several new nonpeptide NPY Y 5 antagonists have appeared in the recent literature and some have been shown to inhibit both NPY-and fasting-induced food intake. 25, 29 Some have significant interactions with non-NPY receptors, while the others have not been rigorously assessed for selectivity and nonspecific interactions. Therefore, in the absence of suitable antagonists, the contribution of the NPY Y 5 receptor to the control of appetite remains uncertain. In the present studies, the role of the NPY Y 5 receptor in the control of food intake was assessed using the newly synthesized NPY Y 5 receptor antagonistFS 25585. In the interpretation of food intake studies featuring new drugs, it is imperative to keep in mind that the number of compounds reported to inhibit food intake far exceeds the number that stimulates food intake. This is because eating in animals is very sensitive to disruption either by malaise, pain or illness or by alterations of behavioral patterns, which prevent the normal expression of appetite. 30, 31 Therefore, the first objective of these studies was to assess the activity of S 25585 rigorously in three separate tests sensitive to the illness-producing/aversive properties of drugsFconditioned taste aversion, sodium appetite and pica.
When animals are presented with a solution having a novel taste such as saccharine and injected with a drug that induces gastrointestinal malaise or nausea, an associative pairing occurs. As a result, the animal will avoid the novel taste in the future because it is associated with recalled feelings of malaise and nausea. This learned taste avoidance is the basis of the conditioned taste aversion paradigm that was used in the present studies. 32 When depleted of sodium, animals avidly consume saline solutions in an attempt to restore their extracellular fluid volume. However, when administered emetic or malaiseinducing substances, the consumption of saline is reliably reduced. Thus, decreased sodium appetite in sodiumdepleted animals can also be used as a reliable marker of malaise and nausea. 33 Pica is the ingestion of non-nutritive substances such as the synthetic white clay kaolin. Pica has been shown to increase after injection of illness-producing agents such as lithium chloride, cyclophosphamide and in response to motion sickness. Even when rats are visually ill and other behaviors such as eating and motility are suppressed, kaolin intake is reliably increased. Thus, kaolin intake may be considered the gold standard since there are no alternative explanations for the phenomenon of pica, as there are for CTA and sodium appetite, except visceral distress. 34, 35 In these studies, the emetic agent lithium chloride produced the expected robust conditioned taste aversion and significantly decreased need-induced sodium appetite. Additionally, the illness induced by cyclophosphamide was associated with significantly enhanced kaolin intake. In marked contrast to these two aversive/illness-producing agents, S 25585 did not produce a conditioned taste aversion, significantly suppress sodium appetite or cause pica at the doses used in these studies. In addition, S 25585 had no significant interaction with over 40 different receptors and channels. On the basis of these observations, S 25585 was assumed to be a suitable tool for investigating the role of the NPY Y 5 receptor in the control of food intake.
Recently, several modified NPY peptides have been synthesized that combine high affinity for the NPY Y 5 receptor with high selectivity. [13] [14] [15] [16] All these potent and selective peptides stimulate food intake, some more than NPY itself. In the present studies, the most selective of these Rats were fasted for 4 h immediately before the dark phase and then food intake and motility were recorded over a 35 min period. At 1 h before commencing measurement, the animals were given S 25585 (7.5 mg/kg, i.p.) or an equivalent volume of either the 10% solutol/10% DMSO vehicle or 0.9% NaCl (2 ml/kg, i.p.).
Results are expressed as mean7s.e. from eight observations in each group except in the motility studies where the fasted+NaCl group is composed of seven observations. Statistics by one-way analysis of variance was followed by the Student-Neumans-Keuls test that compared differences between each group. *Po0.05 from the fasted+solvent group. # Po0.05 from the fasted+NaCl group. One animal in the fasted+S 25585 group had a meal duration of 7 minFa value more than 2 s.d. greater than the group mean. The exclusion of this value produced a mean of 0.8870.25 min (n ¼ 7), which is statistically different from both control groups. ]hNPY into the brain produced a marked increase in food intake that was robustly inhibited by the NPY Y 5 inhibitor S 25585. Taken together with previous findings, the present results firmly establish that selective stimulation of the NPY Y 5 receptor with exogenous peptides is associated with increased food intake.
After release in the brain, NPY would be expected to interact with all NPY receptor subtypes involved in the control of food intake. The critical question of whether the NPY Y 5 receptor subtype plays an important enough role to mediate some or indeed all the actions of NPY on food intake was also assessed in these studies. The results show that blockade of the NPY Y 5 receptor with S 25585 markedly inhibited the increase in food intake produced by NPY. Thus, the results appear to show that when all NPY receptors are stimulated, the NPY Y 5 subtype plays a predominant role in mediating the effects of NPY on food intake.
Whether blockade of the NPY Y 5 receptor could also block the increase in food intake produced by endogenous NPY was the next question posed in these studies. To answer this question, the NPY Y 5 receptor was inhibited after elevation of endogenous NPY levels. In this regard, it has been known for many years that animals both eat and terminate eating in a well-defined series of behavioral events. Observation of this behavioral profile is the basis of the BSS. The BSS is described as progressing from an initial phase of eating, through grooming to an eventual phase of predominantly resting behavior. 36 Drugs that induce nausea, sedation, hyperactivity or affect the palatability of the food have all been shown to disrupt the BSS. 36 As described in the literature, the continuous observation method of measuring the BSS involves the determination of food intake for 40 min just after the beginning of the dark phase. 36 NPY levels in the hypothalamus show a clear circadian rhythm, with the highest levels recorded at the end of the light phase when animals begin to eat the major part of their daily food intake. 5, 37, 38 The BSS imposes a 4 h fast just prior to measurement, which may serve to enhance hypothalamic NPY levels even further. Thus the BSS, when coupled to an assessment of the microstructure of food intake, provides a method of studying patterns of food intake against a background of elevated NPY levels. When administered to the animals just before the beginning of the dark phase, S 25585 significantly reduced food intake but did not appear to disrupt the pattern of the BSS. The classic progression of behaviors that moved from feeding through grooming to end in a period of predominantly resting behavior was observed in both control and S 25585-treated animals. Since S 25585 did not alter the overall pattern of the BSS, these observations serve to strengthen the conclusions of the CTA, sodium appetite and pica studies that the effects of the compound on food intake are not secondary to nonspecific actions of the molecule. In fact, the effect of S 25585 appeared to be highly behavioral specific since it affected only food intake and resting behavior and did not significantly change the expression of other behaviors such as drinking, grooming, sniffing, rearing or the general activity of the animals.
The reduction and earlier termination of eating behavior together with the earlier start and increase in resting behavior induced a shift to the left in the BSSFclassic manifestations of a compound that acts primarily by enhancing satiety. The decrease in meal size and meal duration is in agreement with this conclusion. 39 In addition to an effect on the consummatory phase of food intake, S 25585 also appeared to alter the appetitive phase of food intake as suggested by the marked increase in latency. This finding is in agreement with previous observations that have shown that injections of exogenous NPY into the hypothalamus acts to increase the motivation of animals to eat. 40 The results of the present studies extend these observations by indicating that this property is also shared by endogenous NPY and is apparently mediated by the NPY Y 5 receptor subtype.
Although the results demonstrated that S 25585 influences food intake by interrupting an endogenous control mechanism assumed to be NPY mediated, the possibility remained that appetite was being influenced by an interaction with a receptor/channel not investigated in the initial screening. Clearly, it is not feasible to study the interaction of each NPY Y 5 antagonist with every receptor and channel that could have an influence on food intake since many remain to be discovered. Therefore, the effects of S 25585 on food intake were assessed in the NPY Y 5 mice as these became available at the end of these studies. The knockout mouse can be considered the gold standard for selectivity, since only drugs having effects on receptors/channels other than the NPY Y 5 can affect food intake in this model. Surprisingly, when administered at a dose of 15 mg/kg/day, S 25585 had little effect on food intake and body weight in control mice, but produced a large effect on these parameters in the NPY Y 5 knockout mice. One explanation may be that S 25585 interacts with murine NPY Y 1 and NPY Y 2 receptors. However, more likely the results suggest that non-NPY mechanisms are upregulated in the NPY Y 5 knockout mouse and play a major, if not predominant, role in mediating the effects of S 25585 on food intake. The underlying central or peripheral mechanism(s) responsible for the effect of S 25585 on food intake have not been determined, although an interaction with the newly discovered receptor neuropeptide FF represents an interesting possibility. 41 Since the completion of these studies, several wellcharacterized orally bioavailable NPY Y 5 antagonists that penetrate into the brain have appeared in the literature. These compounds fail to affect either NPY-induced or spontaneous food intake in a variety of animal models. 21, 42 Thus, a consensus is building that the NPY Y 5 receptor does not play an important role in the control of food intake, and the results of these studies are consistent with this view. Despite this, other groups have reported equally well-characterized but nonorally active NPY Y 5 antagonists that can inhibit both NPY-induced food intake and spontaneous food intake in different animal models when administered intraperitoneally. 22 The results of the present study suggest that the activity of these compounds may be due to actions other than the NPY Y 5 receptor blockade. The major difference between all these studies is the presence or absence of the NPY Y 5 antagonists in the peritoneal cavity. Therefore, it is most likely that the presence of high concentrations of the compounds at this site may act to influence systemic pathways involved in the control of food intake. The present studies suggest that identification of these pathways could provide novel leads for the production of a new class of appetite-suppressing drugs.
In conclusion, the results presented in this study do not support the hypothesis that NPY acting through the NPY Y 5 receptor plays a physiologically important role in the initiation and maintenance of food intake. Furthermore, the results underline the necessity of rigorously assessing the selectivity of new NPY Y 5 antagonists in the NPY Y 5 knockout mouse before their use in additional animal studies.
